菲律宾人乳头瘤病毒疫苗接种的成本效果分析
该分析采用比例结果模型,从政府和社会视角评估四种HPV疫苗对9岁女孩常规接种的成本效果。考虑交叉保护时,从政府视角,Cecolin®、Cervarix™和GARDASIL®的每避免DALY成本分别为1210、1300和2043美元;从社会视角分别为173、263和1006美元。直接比较中GARDASIL®被Cervarix™和Cecolin®支配,GARDASIL®9在所有模拟场景下均不具成本效果。
要点
- 考虑交叉保护时,Cecolin®、Cervarix™和GARDASIL®从政府视角均具成本效果。
- 从社会视角,三种疫苗的每避免DALY成本分别为173、263和1006美元。
- GARDASIL®9在所有模拟场景下均不具成本效果。
核心结论
- 与不接种相比,考虑交叉保护时Cecolin®、Cervarix™和GARDASIL®从政府和社会视角均具成本效果,GARDASIL®9在任何模拟场景下均不具成本效果。
研究设计与样本
- 采用比例结果模型,从政府和社会视角评估四种HPV疫苗(Cervarix™、Cecolin®、GARDASIL®和GARDASIL®9)对10个队列9岁女孩常规接种的成本效果。
- 模型参数包括宫颈癌负担、医疗和项目成本、有无潜在交叉保护的疫苗效力及接种覆盖率。
- 采用单变量和概率敏感性分析评估不确定性对模型结果的影响。
主要发现
- 考虑交叉保护时,从政府视角,Cecolin®、Cervarix™和GARDASIL®的每避免DALY成本分别为1210、1300和2043美元;从社会视角分别为173、263和1006美元。
- 直接比较疫苗时,GARDASIL®被Cervarix™和Cecolin®支配。
- 不考虑交叉保护的场景下结果相似,但Cervarix™和GARDASIL®均被Cecolin®支配。
- GARDASIL®9在所有模拟场景下均不具成本效果。
关键数值与推荐
- 政府视角每避免DALY成本:Cecolin® 1210美元、Cervarix™ 1300美元、GARDASIL® 2043美元(考虑交叉保护)。
- 社会视角每避免DALY成本:Cecolin® 173美元、Cervarix™ 263美元、GARDASIL® 1006美元(考虑交叉保护)。
- 不考虑交叉保护时,Cervarix™和GARDASIL®均被Cecolin®支配。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cervical cancer is the second most common cancer among women in the Philippines. Human papillomavirus (HPV) vaccination provides protection from the most common cancer-causing HPV types. This analysis used a proportionate outcomes model to estimate the potential cost-effectiveness of four different HPV vaccine products-Cervarix™, Cecolin®, GARDASIL®, and GARDASIL®9-for routine HPV vaccination of 10 cohorts of 9-year-old girls from the government and societal perspectives. Model parameters included cervical cancer burden, healthcare and program costs, vaccine efficacy with and without potential cross-protection, and vaccination coverage. Univariate and probabilistic sensitivity analyses evaluated the impact of uncertainty on model results. Compared to no vaccination, HPV programs with Cecolin®, Cervarix™, and GARDASIL® are projected to be cost-effective at US$1,210, US$1,300, and US$2,043 per DALY averted, respectively, from the government perspective, and at US$173, US$263, and US$1,006 per DALY averted, respectively, from the societal perspective when cross-protection was considered. When direct comparisons were made across vaccines, GARDASIL® was dominated by Cervarix™ and Cecolin®. In a scenario where cross-protection was not considered, results were similar except that Cervarix™ and GARDASIL® were both dominated by Cecolin®. GARDASIL®9 was not cost-effective under any of the modeled scenarios.
引用
- Llave CL, Uy MEV, Lam HY, et al. The cost-effectiveness of human papillomavirus vaccination in the Philippines. Vaccine. 2022. PMID: 35606237. doi:10.1016/j.vaccine.2022.05.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。